

## ResApp completes COVID-19 study recruitment in India

- ResApp's Indian COVID-19 study has completed recruitment of 337 patients, including over 200 COVID-19 positive cases
- ResApp's US study has recruited its first patient from in-person COVID-19 testing clinic
- ResApp is using data collected in these studies to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone

**Brisbane, Australia, 23 November 2021** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has completed recruitment in its COVID-19 study in India. ResApp will use this data to develop a smartphone-based algorithm to instantly screen for COVID-19 and monitor disease progression.

ResApp's Indian COVID-19 study (Clinical Trials Registry – India: CTRI/2021/09/036581) has recruited 337 patients, including over 200 COVID-19 positive cases, across two study arms in India. Both positive and negative cases were confirmed with gold standard polymerase chain reaction (PCR) pathology testing. Outpatients and inpatients were recruited, with inpatients additionally providing cough sound samples at multiple times during their hospital stay to understand more about disease progression

ResApp's US based study (clinicaltrials.gov: NCT04864535) has recently been expanded to allow recruitment from in-person COVID-19 testing clinics in addition to its existing at-home recruitment. ResApp advises that the first patient has now been recruited in the in-person testing clinic arm of the study. Recruitment in the US study is expected to complete mid-December 2021.

CEO and Managing Director, Dr Tony Keating said: *"We are pleased to report that we have completed recruitment in India ahead of schedule. We are grateful to all the patients for their willingness to participate in the study, as well as the investigators and their teams for their hard work. This is an important milestone in collecting a high-quality dataset to perform the necessary development work to build, train and test machine learning algorithms capable of identifying COVID-19 from cough sounds.*

*"Europe is the midst of a fourth wave of COVID-19 pandemic bringing with it new lockdowns and increased hospitalisation rates. Experts agree that screening and management of COVID-19 will be an ongoing requirement for many years and ResApp is focused on the development of instant smartphone-based applications to fulfill these global needs."*

### About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine



learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

**Contacts**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Executive Director, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*

For personal use only